As a pharmaceutical manufacturer, you may think coding and marking systems are error-prone and at many times difficult to manage. Whether for printing barcodes, 2D codes, expiration dates, lot codes, Data Matrix codes or other data, the pharmaceutical industry is one in which reliable coding is a must, not an option. Counterfeiting has been a huge concern in the pharmaceutical …
Pharma News – Zydus Cadila Buys Six Brands From Merck India
Recently in pharma news, Zydus Cadila announced the Ahmadabad-based company has acquired six brands from Merck India, also referred to as MSD outside of the U.S. and Canada, through its wholly-owned subsidiary Zydus Healthcare Ltd. News reports do not indicate how much Zydus Cadila paid for these brands, which fall in the wound management therapy, cardiovascular, and men and women’s …
Fidia Pharmaceutical Introduces New Packaging For Hyalo Gyn®
Recently it was announced that a global leader in hyaluronic acid products, Fidia Farmaceutical S.p.a. and its wholly owned subsidiary Fidia Pharma USA Inc., introduced new product packaging for its HYALO GYN® vaginal hydrating gel, while the formulation of the product would remain the same. The company specializes in R & D and manufacturing of products based on HA, or …
U.S. Still Largest Market For Medical Devices And Pharmaceuticals
According to The Association for Packaging and Processing Technologies (PMMI), the U.S. remains the largest market for medical devices and pharmaceuticals, even as the demand on a global scale continues to increase. In its report Pharmaceutical and Medical Devices: Trends and Opportunities in Packaging Operations, released by PMMI at PACK and Pharma Expo 2016, the association found that some of …
Pharma News – Novartis Acquires Selexys Pharmaceuticals
Recently in pharma news it was announced that Basel, Switzerland-based Novartis, a global healthcare company, has acquired Oklahoma City-based Selexys Pharmaceuticals, a company specializing in inflammatory and hematological disorders, for $665 million. According to news reports, Selexys was purchased following a Phase II trial focusing on the use of the anti-P-selectin antibody SelG1 for reducing the instance of vaso-occlusive crises …